Key Takeaways
- •5-Amino-1MQ is a small molecule inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme involved in the NAD+ salvage pathway and methyl group metabolism.
- •Preclinical research suggests that NNMT inhibition may shift cellular metabolism away from methyl group consumption and toward NAD+ regeneration, potentially influencing energy balance.
- •Evidence is limited to in vitro (cell culture) and in vivo (rodent) studies; no human clinical trials have been identified as of July 2026.
- •Some foundational studies on NNMT inhibition and metabolic outcomes have been published, but the field is young and replication remains limited.
- •5-Amino-1MQ is not approved for human use and is sold exclusively for laboratory research purposes.
- •Researchers should interpret findings cautiously due to the small number of independent studies and the absence of human safety data.
Key Takeaways
- 5-Amino-1MQ is a small molecule inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme involved in the NAD+ salvage pathway and methyl group metabolism.
- Preclinical research suggests that NNMT inhibition may shift cellular metabolism away from methyl group consumption and toward NAD+ regeneration, potentially influencing energy balance.
- Evidence is limited to in vitro (cell culture) and in vivo (rodent) studies; no human clinical trials have been identified as of July 2026.
- Some foundational studies on NNMT inhibition and metabolic outcomes have been published, but the field is young and replication remains limited.
- 5-Amino-1MQ is not approved for human use and is sold exclusively for laboratory research purposes.
- Researchers should interpret findings cautiously due to the small number of independent studies and the absence of human safety data.
Evidence Quality Summary
| Evidence Area | Strength | Notes |
|---|---|---|
| NNMT inhibition in cell culture | Low to moderate | Consistent findings across a few independent labs; mechanism plausible |
| Rodent metabolic studies | Low | Few studies; most from single research groups; limited replication |
| Human clinical trials | Very low | None identified as of July 2026 |
| Safety / toxicology | Very low | No published formal toxicology studies |
| Mechanistic understanding | Low to moderate | Biochemical pathway well-characterized, but compound-specific data are sparse |
| Question | Current Evidence | |
| Human trials? | No registered human clinical trials identified | |
| Main mechanism? | Inhibition of NNMT, altering NAD+ salvage and methyl group metabolism | |
| Evidence type? | Preclinical only (in vitro and rodent models) | |
| Safety established? | No; no formal toxicology or safety studies published | |
| Approved for human use? | No |
What Is 5-Amino-1MQ?
5-Amino-1MQ, also known as 5-amino-1-methylquinolinium, is a small molecule inhibitor of nicotinamide N-methyltransferase (NNMT). Its IUPAC name is 5-amino-1-methylquinolin-1-ium, and its molecular formula is C₁₀H₁₁N₂⁺ (cationic form). The compound is typically supplied as a salt (e.g., iodide or chloride) for laboratory use. It is structurally related to quinolinium-based compounds and was developed as a tool for studying NNMT function in cellular metabolism.
Proposed Mechanism of Action
5-Amino-1MQ has been reported to inhibit nicotinamide N-methyltransferase (NNMT), an enzyme that transfers a methyl group from S-adenosyl methionine (SAM) to nicotinamide, producing N-methylnicotinamide (MNA). This reaction consumes SAM and diverts nicotinamide away from the NAD+ salvage pathway. By inhibiting NNMT, 5-Amino-1MQ is hypothesized to increase intracellular nicotinamide availability, thereby supporting NAD+ regeneration via the salvage pathway. Research in this area suggests that NNMT inhibition may also reduce methyl group consumption, potentially altering epigenetic regulation and energy metabolism. It is important to note that while the biochemical pathway is well characterized, direct evidence linking 5-Amino-1MQ to specific metabolic outcomes in vivo remains limited.
Preclinical Research Findings
Preclinical studies have explored 5-Amino-1MQ primarily in cell culture and rodent models. In vitro experiments using adipocytes and hepatocytes have shown that NNMT inhibition with 5-Amino-1MQ can increase NAD+ levels and alter gene expression related to energy expenditure. Some rodent studies have reported that administration of 5-Amino-1MQ led to reduced body weight gain and improved glucose tolerance in diet-induced obesity models. These effects were associated with changes in adipose tissue metabolism and increased energy expenditure.
However, the evidence base is narrow. Most published studies originate from a small number of research groups, and independent replication is lacking. The compound has not been tested in any human clinical trials, and its pharmacokinetics, bioavailability, and long-term effects remain uncharacterized. Researchers should treat these findings as preliminary and hypothesis-generating.
Evidence Limitations and Retractions
The literature on 5-Amino-1MQ is limited in both volume and scope. As of July 2026, no registered human clinical trials were identified on ClinicalTrials.gov for this compound. The majority of published studies are from single laboratories, and independent validation is minimal. No retractions or expressions of concern have been issued for 5-Amino-1MQ-specific studies at this time, but the broader field of NNMT inhibition has seen some contested findings regarding metabolic outcomes. Researchers are advised to critically evaluate source studies and consider the potential for publication bias.
Safety Considerations
No formal toxicology or safety pharmacology studies for 5-Amino-1MQ have been published. The compound is not approved for human use by any regulatory agency. Potential safety concerns include off-target effects on methyl group metabolism, interference with SAM-dependent methylation reactions, and unknown toxicity profiles. Because NNMT is expressed in multiple tissues, systemic inhibition could have unintended consequences. Researchers should handle 5-Amino-1MQ with appropriate laboratory safety precautions and avoid any form of human or animal self-administration.
Current Research Status
5-Amino-1MQ remains a research chemical with limited but growing preclinical evidence. Current investigations are focused on its role in NAD+ metabolism, energy balance, and potential applications in metabolic disease models. The compound is not yet a validated therapeutic target, and much of the mechanistic understanding relies on indirect pathway analysis. Future research will require independent replication, dose-response studies, and rigorous pharmacokinetic characterization. For researchers interested in the broader context of peptide and small molecule research, the Research Hub provides additional resources. A glossary of related terms is available at the Peptide Glossary.
Frequently Asked Questions
What is the primary research application of 5-Amino-1MQ?
5-Amino-1MQ is used in preclinical research to study the role of NNMT in NAD+ salvage, methyl group metabolism, and energy homeostasis. It is not intended for human use.
Has 5-Amino-1MQ been tested in humans?
No. As of July 2026, no human clinical trials have been conducted or registered for 5-Amino-1MQ. All available evidence comes from in vitro and rodent studies.
How does 5-Amino-1MQ differ from other NAD+ boosters like nicotinamide riboside?
5-Amino-1MQ inhibits NNMT, which may indirectly increase nicotinamide availability for NAD+ synthesis. In contrast, nicotinamide riboside and nicotinamide mononucleotide are direct NAD+ precursors. The mechanisms and metabolic consequences are distinct.
Is 5-Amino-1MQ considered safe for laboratory use?
Standard laboratory safety precautions should be followed. No formal toxicology data are available, and the compound should be handled as an uncharacterized research chemical.
References
- Kraus, D., Yang, Q., Kong, D., Banks, A. S., Zhang, L., Rodgers, J. T., ... & Spiegelman, B. M. (2014). "Nicotinamide N-methyltransferase knockdown protects against diet-induced obesity." Nature, 508(7495), 258-262.
- Neelakantan, H., Vance, V., Wetzel, M. D., Wang, H. Y., McHardy, S. F., Finnerty, C. C., ... & Watowich, S. J. (2018). "Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in mice." Biochemical Pharmacology, 147, 141-152.
- Ulanovskaya, O. A., Zuhl, A. M., & Cravatt, B. F. (2013). "NNMT promotes epigenetic remodeling in cancer by creating a metabolic methylation sink." Nature Chemical Biology, 9(5), 300-306.
- van Haren, M. J., Taig, R., Kuppens, J., & van der Stelt, M. (2021). "Inhibitors of nicotinamide N-methyltransferase: A new class of potential therapeutics for metabolic disorders." Drug Discovery Today, 26(11), 2674-2685.
Research-Only Disclaimer
5-Amino-1MQ is sold for laboratory research purposes only. It is not approved for human consumption, veterinary use, or any clinical application. This article is for informational and educational purposes and does not constitute medical advice. Researchers should consult relevant safety data sheets and institutional guidelines before handling this compound. For further details, please see the Research Disclaimer.
Reviewed by the Volta Peptides Research Team